v3.25.3
Information related to Opella, presented within assets held for sale and discontinued operations (Details) - EUR (€)
€ / shares in Units, € in Millions
 1 Months Ended 6 Months Ended
Apr. 30, 2025
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Disclosure of analysis of single amount of discontinued operations [line items]        
 Property, plant and equipment owned       € 760
 Right-of-use assets       116
 Goodwill       7,255
 Other intangible assets       2,928
 Inventories       600
Accounts receivable       989
Other assets       841
Total assets held for sale       13,489
Lease liabilities       112
 Non-current provisions and other non-current liabilities       204
Accounts payable       797
Current provisions and other current liabilities       570
Other liabilities       448
Total liabilities related to assets held for sale       € 2,131
Net sales and other revenues [1]   € 1,736 € 2,645  
Operating income [1]   266 277  
Gain on disposal of Opella before tax   2,781 0  
Income before tax and investments accounted for using the equity method, including gain on disposal of Opella before tax   3,039 278  
Income tax expense [2]   (158) (85)  
Net income from discontinued operations (Opella) [3]   € 2,881 € 202 [4]  
Average number of shares outstanding [3]   1,225,500,000 1,249,400,000 [4]  
Average number of shares after dilution [3]   1,230,700,000 1,253,800,000 [4]  
Basic earnings per share [3]   € 2.34 € 0.16 [4]  
Diluted earnings per share [3]   € 2.33 € 0.16 [4]  
Opella Business        
Disclosure of analysis of single amount of discontinued operations [line items]        
Income tax expense   € 88    
Net income from discontinued operations (Opella) € 2,700      
[1] For the first half of 2025, these lines include the net sales and operating income of Opella until the date of loss of control date (see Note B.1.).
[2] In 2025, this line includes an expense of €88 million related to the tax impact on the gain arising on the loss of control of Opella.
[3] These unaudited condensed half year consolidated financial statements as of June 30, 2025 should be read in conjunction with Sanofi’s audited consolidated financial statements as of December 31, 2024.
[4] Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.